These substances are related to the DEA’s interest in researching hallucinogenic controlled products for clinical tests and research. The DEA asserts that it wants to support the regulated trials of schedule 1 substances, so increasing the production quota explains why this move is essential. The DEA also wants to research the requirements for manufacturing new drugs and the kind of impact marijuana has on the body. These steps are taken to work towards the Food and Drug Administration’s possibilities to approve a new drug.
A first-person review of the hemp-derived THC cocktail base I poured at our Cannabis Cup…
Every paper mill in the world still runs on the continuous-web design a Frenchman patented…
A new AI-assisted sci-fi satire from filmmaker Dan Levy Dagerman and the Space Weed Universe…
Spain has increased penalties for electricity theft linked to indoor cannabis cultivation after Endesa reported…
How a 52-year-old first-time grower turned trial and error into a show-stopping harvest The first…
This is the legacy knowledge drain, and it is the quiet catastrophe nobody in the…